【網站推薦】Oral PrEP Learning Resource Package

點選圖片前往網站

【新知】Is PrEP making a difference? Top HIV researchers provide answers

July 23, 2017, by Emily Newman

BETA is attending and reporting from the 2017 International AIDS Society conference on HIV Science this week in Paris, France from July 23 to 26—bringing you the latest news, updates, and research on HIV treatment and prevention.

As countries, cities and agencies worldwide ramp up their investment in pre-exposure prophylaxis (PrEP) services for people at risk for HIV, many are wondering: Is this strategy working in the “real world”—outside the safe parameters of clinical trials?

At the International AIDS Society conference this week, three researchers offered evidence to this point. Here’s what we learned about how the scale-up of PrEP health services (along with other PrEP awareness and educational campaigns) is helping to reduce the number of new HIV infections in communities and countries around the world.

【會議】AIDS 2018 ( 22nd International AIDS Conference )

會議詳情網址：AIDS 2018

AIDS 2018 Conference Objectives

Convene the world’s experts to advance knowledge about HIV, present new research findings, and promote and enhance global scientific and community collaborations in synergy with other health and development sectors.

Promote human rights based and evidence-informed HIV responses that are tailored to the needs of particularly vulnerable communities, including people living with HIV, displaced populations, men who have sex with men, people in closed settings, people who use drugs, sex workers, transgender people, women and girls and young people.

Activate and galvanize political commitment and accountability among governments, donors, private sector and civil society for an inclusive, sustainable and adequately financed, multi-sectoral, integrated response to HIV and associated coinfections and comorbidities.

Address gaps in and highlight the critical role of HIV prevention, in particular among young people in all their diversity and its integration in a range of health care settings.

Spotlight the state of the epidemic and the HIV response in Eastern Europe and Central Asia with a focus on investments, structural determinants and services.

【UPDATE】 Leading scientists celebrate progress towards 90-90-90 targets

原文網址：Leading scientists celebrate progress towards 90-90-90 targets

25 JULY 2017

Hundreds of the world’s leading HIV researchers, programme planners and implementers and civil society advocates gathered prior to the 2017 IAS Conference on HIV Science to assess progress towards the 90-90-90 targets. The workshop, sponsored by the International Association of Providers of AIDS Care (IAPAC) and UNAIDS, in partnership with the Global Network of People Living with HIV, focused on the latest data on progress and on new opportunities to continue to speed gains towards the 90-90-90 milestones.

The targets were launched by UNAIDS in 2014 to accelerate progress so that, by 2020, 90% of all people living with HIV know their HIV status, 90% of all people with diagnosed HIV are accessing sustained antiretroviral therapy and 90% of all people accessing antiretroviral therapy are virally suppressed. In 2016, for the first time, more than two-thirds of people living with HIV knew their HIV status and more than half of all people living with HIV had access to antiretroviral therapy.

【UNAIDS UPDATE】 9th AIDS conference on science opens in Paris

原文網址：9th AIDS conference on science opens in Paris

24 JULY 2017

More than 6 000 HIV professionals from around the world have gathered in Paris for the 9th IAS Conference on HIV Science. The four-day conference is one of the largest open scientific meetings on HIV, organized by the International AIDS Society (IAS) in partnership with the French National Agency for Research on AIDS and Viral Hepatitis (ANRS).

This year’s conference will prioritize basic science, a prerequisite step to ending the HIV epidemic and feature studies that shine a light on the specific needs of key populations, including young people, transgender people, men who have sex with men, sex workers and people who inject drugs.

The conference was officially opened on Sunday evening by French Health Minister Agnes Buzyn, UNAIDS Executive Director Michel Sidibé, French economist Esther Duflo, Giovanna Rincon, President of the ACCEPTESS-T association and officiated by Linda-Gail Bekker, President of IAS and International Scientific Chair of IAS 2017 as well as IAS 2017 Local Scientific Chair and former director of ANRS.

Global HIV funding has many preoccupied at the Paris conference. Funding cuts would devastate HIV research and treatment programmes, stalling or undoing recent progress highlighted in the latest UNAIDS report released 20 July. IAS reiterated that their shared objective was to ensure that science remains the backbone of the global AIDS response saying funding was critical to end the HIV epidemic.

The conference runs from 23 July to the 26th.

臺灣暴露前口服預防性投藥使用指引

指引下載網站：台灣愛滋病學會

【NEWS】FDA Approves Generic Truvada for HIV Treatment and PrEP

However, Gilead Sciences, the brand-name manufacturer of Truvada, insists a generic version “will not be immediately available.”

June 9, 2017 • By Benjamin Ryan

In a move that has taken HIV advocates by surprise and stewed considerable confusion, the U.S. Food and Drug Administration (FDA) has approved a generic formulation of Gilead Sciences’ blockbuster antiretroviral (ARV) Truvada (tenofovir disoproxil fumarate/emtricitabine). This decision could have major implications for the future cost of Truvada, to insurers and consumers alike.

However, Gilead insisted in a statement, “A generic version of Truvada will not be immediately available. It’s important to note that there are a number of factors involved in commercialization that are not tied directly to FDA approval.”